KR0173814B1 - Health aid food comprising the extract of rosa rugosa thunb - Google Patents
Health aid food comprising the extract of rosa rugosa thunb Download PDFInfo
- Publication number
- KR0173814B1 KR0173814B1 KR1019950026833A KR19950026833A KR0173814B1 KR 0173814 B1 KR0173814 B1 KR 0173814B1 KR 1019950026833 A KR1019950026833 A KR 1019950026833A KR 19950026833 A KR19950026833 A KR 19950026833A KR 0173814 B1 KR0173814 B1 KR 0173814B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- butanol
- hot water
- residue
- methanol
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 32
- 235000013305 food Nutrition 0.000 title claims 2
- 235000000659 Rosa rugosa Nutrition 0.000 title description 2
- 240000006066 Rosa rugosa Species 0.000 title description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 title 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims abstract description 46
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 39
- 238000000605 extraction Methods 0.000 claims abstract description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 17
- 230000034659 glycolysis Effects 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 5
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 9
- 235000015872 dietary supplement Nutrition 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 239000002021 butanolic extract Substances 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims 2
- 239000002034 butanolic fraction Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 239000008280 blood Substances 0.000 abstract description 16
- 210000004369 blood Anatomy 0.000 abstract description 16
- 239000003472 antidiabetic agent Substances 0.000 abstract description 6
- 229940126904 hypoglycaemic agent Drugs 0.000 abstract description 6
- 239000003440 toxic substance Substances 0.000 abstract description 3
- 230000010030 glucose lowering effect Effects 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 231100000614 poison Toxicity 0.000 abstract description 2
- 235000002597 Solanum melongena Nutrition 0.000 abstract 1
- 244000061458 Solanum melongena Species 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000000144 pharmacologic effect Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 230000003345 hyperglycaemic effect Effects 0.000 description 3
- 239000000401 methanolic extract Substances 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000002024 ethyl acetate extract Substances 0.000 description 2
- 230000002414 glycolytic effect Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- YLKUQAFDYMLBCK-UHFFFAOYSA-N butan-1-ol;ethyl acetate Chemical compound CCCCO.CCOC(C)=O YLKUQAFDYMLBCK-UHFFFAOYSA-N 0.000 description 1
- 239000002026 chloroform extract Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000002035 hexane extract Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/10—Drying, dehydrating
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
본 발명은 해당화 근부에서 추출된 혈당강하제 및 이의 제조방법에 관한 것이다. 본 발명은 해당화 근부의 열수 추출물과 메탄올 또는 에탄올의 혼합물을 부탄올로 추출하고 난 뒤의 추출잔사를 포함하는 혈당강하제이다. 부탄올로 추출한 뒤의 추출잔사는 혈당강하효과가 탁월할 뿐만 아니라 해당화 근부가 본래 가지는 독성물질이 완전히 제거된 것이다.The present invention relates to a blood glucose lowering agent extracted from the root of the glycolysis and a method for producing the same. The present invention is a mixture of hot water extract and methanol or ethanol It is a hypoglycemic agent that contains the extraction residue after extraction with butanol. The extraction residue after extraction with butanol not only has an excellent effect on lowering blood sugar, Eggplant is a complete removal of toxic substances.
Description
본 발명은 생약재료에서 추출된 혈당강하제, 더욱 상세하게는 해당화 근부에서 추출된 혈당강하제 및 이의 제조방법에 관한 것이다.The present invention relates to a hypoglycemic agent extracted from the herbal medicine, more specifically, a hypoglycemic agent extracted from the root of the glycolysis and a method for producing the same.
해당화(Rosa rugosa Thunb)는 낙엽 관목으로서 해변 모래땅, 산록에서 자라며, 수직적으로는 표고 1600m 이하에서, 수평적으로는 전남, 경북, 충남, 강원, 경기, 황해, 평안, 함남북도, 지리적으로는 일본, 만주, 캄챠카에 분포한다(정태현, 한국식물도감, 목본부, 이문사, p.177, 1974). 이 식물의 약학적인 이용은 꽃의 경우, 토혈(吐血), 풍비(風痺), 월경과다 등에 이용되고 있으며, 지하부는 우리나라 민간에서 당뇨병의 치료에 사용되어 있다(양한석외 3인, 약학회지, 31(6), 394(1987)).Rosa rugosa Thunb is a deciduous shrub that grows on sandy beaches and foothills, vertically below 1600m, horizontally in Jeonnam, It is distributed in Gyeongbuk, Chungnam, Gangwon, Gyeonggi, Yellow Sea, Pyeongan, North Hamnam, and Japan, Manchuria, and Kamchatka (Jung Tae-hyun, Korean Plant Book, Wood Headquarters, Lee Mun-sa, p.177, 1974). The pharmacological use of this plant is used for flowers, bleeding, wind, and excessive menstruation. It has been used for the treatment (Yang, Han Seok et al., Journal of Pharmacy, 31 (6), 394 (1987)).
본 식물의 혈당강하 작용에 대한 연구는 일부 보고 되어있다. 송(송선두외 2명, 연세의대 논문집, 10, 125(1977))등은 알록산(alloxan)으로 고혈당을 유발시킨 쥐에 해당화 지하부의 열수 추출물을 경구 투입하여 약간의 혈당강화 효과가 있음을 보고하였다. 이명열(이명열, 중앙대학교 석사학위논문, 1982, 조선대 제약연구, 6, 19(1984))등은 해당화 근피의 열수 추출물, 메탄올 추출물 및 사포닌을 실험용 고혈당증의 집토끼에 적용하여 메탄올 추출물 및 사포닌이 혈당강하 효과를 나타낸다는 것을 밝혔다. 한편, 양(약학회지, 31(6), 394(1987)등은 해당화 근부의 메탄올 추출물의 경우, 혈당강화 효과는 없으나 고지혈중에는 효과가 있다고 보고하였다.Some studies on the hypoglycemic effect of the plant have been reported. Song (Song Sun Doo and two others, Yonsei University Medical School, 10, 125 (1977)) The hypoglycemic effect was reported by oral administration of hot water extracts from the glycolysis subterranean rats induced hyperglycemia with alloxan. Lee, Myung-Yeol (Myung-Yeol Lee, Master's Thesis, Chung-Ang University, 1982, Chosun University, Pharmaceutical Research, 6, 19 (1984)) It was found that methanol extract and saponin showed hypoglycemic effect when applied to rabbits of experimental hyperglycemia. On the other hand, Yang (Pharmaceutical Journal, 31 (6), 394 (1987) and others reported that methanol extracts from the root of glycolysis have no effect on blood glucose-enhancing effects but are effective on hyperlipidemia.
이상과 같이 해당화 근부 또는 근피의 일부 추출물의 경우, 혈당강하에 효과가 있다고 알려져 있으나, 이들은 1주일 정도의 짧은 기간 동안에 관찰된 결과이며, 또한 이들 효과의 대부분은 췌장의 Langerhans inland내의 β-cell을 자극하여 인슐린 분비 촉진을 유발하는 것으로 생각되고 있다. 따라서 인슐린 분비 기관이 거의 파괴된 경우, 즉, 인슐린 의존성 당뇨병의 경우에도 혈당 강하 효과가 있는지 밝혀져 있지 않을 뿐만 아니라 장기간 치료시에는 어떠한 영향을 미치는가 하는 것에 대해서는 의문으로 남겨져 있었다. 또한, 민간요법에서 당뇨에 효과가 있다고하는 해당과 근부의 열수 추출물은 수차례이상 복용하면 구토와 복통 등의 부작용을 유발하는 문제점이 있어 왔으며 상술한 것처럼 실제 인위적으로 유발시킨 인슐린 의존성 고혈당증에는 그 효과가 매우 낮거나 거의 없었다.As mentioned above, some extracts of the corresponding root or muscle are known to be effective in lowering blood sugar, but they are observed in a short period of about 1 week. In addition, most of these effects are thought to stimulate the secretion of β-cells in the pancreatic Langerhans inland and to promote insulin secretion. have. Therefore, it is not known whether the hypoglycemic effect of insulin secretion is almost destroyed, that is, insulin dependent diabetes mellitus. The effect of long-term treatment remains questionable. In addition, the number of hot water in the periphery and roots that are effective in diabetes in folk medicine The extract has been problematic in causing side effects such as vomiting and abdominal pain when taken more than several times. The effect was very low or very little.
본 발명은 해당화 근부의 열수 추출물을 여러가지 용제로 추출하는 과정에서 부탄올로 추출하였을 때 독성물질은 추출액으로 제거되고 추출잔사 구분에 혈당강하를 주도하는 성분이 존재한다는 사실을 발견하고 이러한 발견을 토대로 완성되었다. 일반적으로 생리활성물질을 용제로써 추출해내는 일반적인 방법과는 대조되는 것이다.The present invention, when extracted with butanol in the process of extracting the hot water extract in the roots of the glycolysis roots with various solvents, the toxic substances are removed by the extract and the blood sugar drop in the extraction residue The discovery that the dominant component exists is complete based on this finding. Generally contrasted with the general method of extracting the bioactive substance as a solvent. will be.
본 발명의 목적은 생약재료를 이용하여 부작용이 없고 인슐린 의존성 고혈당증에도 치료가 가능한 혈당강하제 및 이의 제조방법을 제공하기 위한 것이다.An object of the present invention is to provide a hypoglycemic agent and a method for producing the same, which have no side effects and can be treated with insulin-dependent hyperglycemia using herbal ingredients.
본 발명의 또다른 목적은 혈당강하에 효과가 있는 건강보조식품을 제공하기 위한 것이다.Another object of the present invention to provide a dietary supplement that is effective in lowering blood sugar.
본 발명의 이러한 목적은 해당화 근부의 열수 추출물에 메탄올 또는 에탄올과 같은 저급 알코홀류를 가하여 그 가용분을 제조하고 이를 부탄올로 추출하고 난 뒤의 추출잔사를 포함하는 혈당강화 효과가 있는 건강보조식품 또는 혈당강하제에 의하여 달성된다.The object of the present invention is to add a lower alcohol such as methanol or ethanol to the hydrothermal extract of the glycolysis root to prepare a soluble component and extract it with butanol. It is achieved by a dietary supplement or a hypoglycemic agent having a glycemic-enhancing effect, including the latter residue.
상기 혈당강하제는The hypoglycemic agent
1) 해당화 근부를 열수 추출하는 단계;1) extracting hot water from the corresponding root;
2) 상기 열수 추출물을 메탄올 및 에탄올과 같은 저급 알코홀류로 추출하여 가용분을 얻는 단계;2) extracting the hot water extract with lower alcohols such as methanol and ethanol to obtain a soluble component;
3) 상기 저급 알코홀 가용분에 추출용매로 부탄올을 첨가, 추출하는 단계; 및3) adding and extracting butanol as an extraction solvent to the lower alcohol soluble powder; And
4) 상기 부탄올 분액을 제거하는 단계에 의하여 제조된다.4) prepared by removing the butanol aliquot.
상기 부탄올 추출후의 추출잔사가 혈당강하의 활성이 있는 분획이다.The extraction residue after the butanol extraction is a fraction having an activity of lowering blood sugar.
상기 해당화 근부는 열수 추출하기 위하여 분쇄 또는 미분화되는 것이 바람직하다.The glycolytic roots are preferably ground or micronized to extract hot water.
열수 추출액은 다음 단계로 그대로 사용될 수 있으나 다음 단계에 사용되기 전에 동결건조하여 분말화할 수 있다. 이 열수 추출물의 분말에 저급 알코홀류인 메탄올 또는 에탄올을 가하여 그 가용분을 얻는다. 특히 메탄올이 바람직하다. 이 알코홀 혼합물을 부탄올로 추출하기 전에 헥산, 클로로포름 및/또는 에틸아세테이트로 극성에 따라 추출해 낼 수 있다.The hot water extract may be used as it is in the next step, but may be lyophilized and powdered before being used in the next step. Which is a low level alcoholic to powder of this hydrothermal extract Methanol or ethanol is added to obtain the soluble component. In particular, methanol is preferable. Hexane, chloroform and / or before extraction of this alcohol mixture with butanol Ethyl acetate can be extracted depending on the polarity.
이하 실시예에 의하여 본 발명을 상세히 설명한다. 그러나 이러한 실시예에 의하여 본 발명의 범위가 제한되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to Examples. However, the scope of the present invention is not limited by these examples.
[실시예 1]Example 1
[해당화 근부 추출물의 제조][Preparation of Glycylated Root Extract]
해당화 뿌리는 전주시 소재 한약 재료상에서 구입하였다. 풍건된 이들 뿌리는 띠톱으로 칩(chip)화 시킨다음 소형 윌리밀(Willy mill)로 분말화 하고 40-80메쉬 부분을 취하여 추출시료로 사용하였다. 열수 추출은 5리터 용량의 삼각플라스크에 해당화 뿌리분말 500g(절건 중량)과 3ℓ의 증류 이온교환수를 넣고 60분간 서서히 자비시키면서 행하였다. 추출후 내용물은 충분히 냉각시키고 여과 및 원심분리하여 추출잔사와 추출물로 나누었다. 잔사를 제거한 후의 추출물은 동결건조하여 분말상으로 하였다. 동결건조후 열수 추출물의 중량은 49.9g으로 해당화 근부분말 절건중량에 대하여 10중량%에 해당하였다. 열수 추출물의 동결건조 분말 5g(절건 중량)을 취하여 여기에 메탄올을 처리하고 교반, 원심분리하였다. 얻어진 메탄올 가용부는 50℃ 이하에서 감압농축, 진공건조시켰다. 건조후의 메탄올 가용부의 양은 3.17g이었다. 메탄올 가용부는 다음 추출을 위하여 소량의 증류 이온 교환수로 녹였다. 그후 이들은 헥산, 클로로포름, 에틸아세테이트, 부탄올로 추출하였다. 각각의 추출물중 헥산, 클로로포름 및 에틸아세테이트 추출물은 극히 소량이었으며 대부분은 부탄올 및 부탄올 추출후의 잔사로서 각각 1.86g 과 1.13g이었다.The root of the flower was purchased from the herbal medicine material in Jeonju. These dried roots are chipped with a band saw and then powdered into a small Willy mill. 40-80 mesh portions were taken and used as extraction samples. Hot water extraction is equivalent to a 5 liter Erlenmeyer flask. 500 g of root powder (dry weight) and 3 liters of distillation. Addition of ion-exchanged water was carried out for 60 minutes while slowly boiling. After extraction, the contents were sufficiently cooled, filtered, and centrifuged to separate the extraction residue and the extract. Residue The extract after removal was lyophilized to form a powder. After lyophilization, the weight of the hot water extract was 49.9 g, which was 10% by weight based on the dry weight of the corresponding root powder. It corresponded. 5 g (dry weight) of the lyophilized powder of the hydrothermal extract was taken, treated with methanol, stirred and centrifuged. The obtained methanol soluble part is 50 degreeC It concentrated under reduced pressure and vacuum-dried below. The amount of methanol soluble part after drying was 3.17 g. Methanol solubles are charged with a small amount of distilled ion-exchanged water for the next extraction. Melted. Then they were extracted with hexane, chloroform, ethyl acetate and butanol. Hexane, chloroform and ethyl acetate extracts in each extract are extremely It was a small amount, most of which was 1.86 g and 1.13 g after the butanol and butanol extraction, respectively.
[실시예 2]Example 2
[혈당강하 활성구분의 입증][Proof of Hypoglycemic Activity Classification]
해당화 근부의 열수 추출물과 상술한 각 추출물 및 잔사부분의 혈당강하 활성 구분을 검토하여, 인슐린 의존형 당뇨쥐에 있어서 뛰어난 효과를 나타내는 구분이 있음을 입증하였다.Examination of the hypoglycemic activity of the hydrothermal extracts of the oxidized root and each of the extracts and residues described above shows the distinctive effect of insulin-dependent diabetic rats. Proved.
1) 고혈당의 유발과 혈당강하 시험1) Induction of hyperglycemia and hypoglycemic test
실험용쥐(150-200g)에 스트렙토조토신을 주사하여 인위적으로 고혈당을 유발시켰다. 이들 쥐들은 2주간 사육하여 충분하게 인슐린 의존형으로 한 후 각 추출물 및 잔사 2-4mg이 함유된 물 150ml를 매일 주었다. 혈당의 측정은 초기를 제외하고는 대부분 일주일 간격으로 측정하였다. 그리고 혈당 강하 효과가 뛰어난 부탄올 추출후의 잔사의 경우 실험시의 혈당치가 정상주와 거의 같은 수준으로 떨어진 이후에는 이들 잔사의 투여를 중지하고 약리 효과의 지속성을 검토하였다.High blood sugar was induced artificially by injecting streptozotocin into experimental mice (150-200 g). These mice were reared for two weeks to fully insulin-dependent. 150 ml of water containing 2-4 mg of extract and residue were given daily. Blood glucose was measured at most weekly intervals except for the early days. And blood sugar drop In the case of the residue after extraction of butanol, which is highly effective, the administration of these residues is stopped and the pharmacological effect Persistence was reviewed.
2) 시험 결과2) test result
기존에 민간에서 널리 알려진 해당화 뿌리의 열수 추출물은 표 1에서 나타낸 것처럼 인슐린 의존성 당뇨쥐에서의 혈당 강하 효과는 거의 인정되지 않았다. 또한 메탄올 추출물의 경우 약간의 혈당 강하 효과가 있는것 같으나, 그 효과는 오차범위에 있어 유의성이 인정되지 않았다. 이러한 결과로 부터 메탄올 추출물의 경우 열수 추출물과 같이 인슐린 의존성 당뇨에 있어서는 그 효과를 인정할 수 없었다. 이들 추출물 이외에도 에틸아세테이트 및 부탄올 추출물에 대한 혈당 강하 효과를 검토하였으나 전혀 효과가 없었다.The hot water extracts of the well-known roots of glycolysis, which have been widely known in the folk field, showed little hypoglycemic effect in insulin-dependent diabetic rats as shown in Table 1. In addition, methanol extract seems to have a slight hypoglycemic effect, but the effect was not recognized in the margin of error. From these results, methanol In the case of the extract, the effect was not recognized in insulin-dependent diabetes like the hydrothermal extract. In addition to these extracts, ethyl acetate and butanol extracts The hypoglycemic effect was examined, but there was no effect at all.
한편, 표 1에 나타낸 것처럼 부탄올 추출후의 잔사 구분은 투여 1주일후에 이미 55%의 혈당 감소가 일어났으며, 2주후에는 정상쥐와 거의 같은 수준으로 유지하였다. 그 결과 약 2주간 그 약리 작용의 지속이 가능하였으며, 투여 중지 후 3주째에는 의의있는 혈당의 상승이 인지되었으며, 이들에 다시 부탄올 추출후 잔사를 투여한지 1주일째 부터 다시 의의있는 혈당강하가 일어났다.On the other hand, as shown in Table 1, the residue classification after butanol extraction had a blood sugar reduction of 55% after 1 week of administration, and after 2 weeks, it was almost the same level as that of normal mice. Maintained. As a result, the pharmacological action was continued for about 2 weeks, and significant blood glucose levels were recognized at 3 weeks after discontinuation, but again, butanol Significant hypoglycemia occurred again one week after the residue was administered.
[실시예 3]Example 3
[급성독성시험][Acute Toxicity Test]
실시예 1에서 제조한 부탄올 추출후의 잔사에 대한 급성 독성 시험은 중량 15-25g의 마우스에 대하여 실시하였다. 마우스를 6마리씩 2개군으로 나누어 하루에 복강내 주입의 경우 1,500mg/kg, 구강내 주입의 경우 10,000mg/kg으로 실시한 결과 2주일후에도 모두 생존하였다. 즉 실시예 1의 부탄올 추출후 잔사는 급성 독성은 거의 없는 것으로 판단되었다.The acute toxicity test for the residue after butanol extraction prepared in Example 1 was carried out on mice weighing 15-25 g. Divide the mouse into two groups of six At 1,500 mg / kg for intraperitoneal injection and 10,000 mg / kg for oral injection, all survived 2 weeks later. Of Example 1 After butanol extraction, the residue was considered to have little acute toxicity.
한편, 실시예 1에서 부탄올 추출물의 경우 감압농축중 부탄올에 대한 용해도가 낮은 물질이 침전하였다. 이 침전물은 전체 부탄올 추출물에 대하여 극소량에 지나지 않으나, 이들을 고혈당증의 쥐에게 혈당 강하 실험과 같은 양으로 투여하였을 경우, 의의 있는 혈당강하 효과를 나타내었으나, 1주일간의 투여로 50%의 치사율을 나타내어 이 침전부에 강한 독성이 존재한다는 것을 정성적으로 확인하였다.Meanwhile, in the case of the butanol extract in Example 1, a substance having low solubility in butanol was precipitated during the vacuum concentration. This precipitate is present in very small amounts relative to the total butanol extract. However, when they were administered to the hyperglycemic rats in the same amount as the hypoglycemic experiment, there was a significant hypoglycemic effect. A mortality of 50% was shown to qualitatively confirm the presence of strong toxicity in this precipitate.
상기 실시예에서 보는 바와 같이 부탄올 추출후의 잔사 구분에서 뛰어난 혈당 강하 효과가 있다는 것을 알 수 있었다. 즉 혈당 강하 효과가 있는 약리성분의 대부분이 이 구분에 모여있다는 것을 알 수 있었다. 그 약리작용을 나타내는 성분은 단일 성분계가 아니며, 복합적으로 작용하는 것으로 추정되었다. 부탄올 추출후 잔사 구분을 고혈당이 유발된 쥐에게 2주간의 투여함에 의하여 고혈당쥐는 정상 혈당을 유지하며, 그후 이들 추출물의 투여를 중지하여도 그 효과가 약 2주간이나 지속되었다. 이러한 혈당 강하 및 지속효과가 해당화 근부의 부탄올 추출후의 잔사에 존재한다고 하는 사실은 지금까지 보고된 예가 없다. 즉 본 연구에 의하여 지금까지 미미한 효과밖에 관찰되지 않았던 해당화 근부에서의 혈당 강하 작용을 하는 특징적인 활성 구분이 밝혀졌다는 것이다.As shown in the above example, it was found that there was an excellent blood sugar lowering effect in the residue fraction after butanol extraction. Of pharmacological ingredients It can be seen that most of them are gathered in this division. The components exhibiting the pharmacological action are not a single component system, but are assumed to act in combination. Butanol After the extraction, the hyperglycemic mice maintain normal blood glucose by administering the residue to the hyperglycemic-induced rats for 2 weeks. It lasted about two weeks. The fact that such blood glucose lowering and sustaining effects exist in the residue after butanol extraction in the vicinity of glycolysis has not been reported so far. In other words This study revealed a characteristic activity that lowers blood glucose in the glycolytic root, which has only been observed to be insignificant.
또한 상기 실시예 3에서 보는 바와 같이 부탄올로 추출하지 않는 잔사는 독성물질을 함유하고 있는 것으로 생각되고 이것은 종래 민간 요법에서 해당화 뿌리를 달여 먹는 경우에 복통 등의 부작용에 대한 간접적인 해명이 될 것이다.In addition, as shown in Example 3, the residue which is not extracted with butanol is considered to contain a toxic substance, and this is the conventional folk remedies. Decoction will be an indirect explanation for side effects such as stomach pain.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019950026833A KR0173814B1 (en) | 1995-08-24 | 1995-08-24 | Health aid food comprising the extract of rosa rugosa thunb |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019950026833A KR0173814B1 (en) | 1995-08-24 | 1995-08-24 | Health aid food comprising the extract of rosa rugosa thunb |
Publications (2)
Publication Number | Publication Date |
---|---|
KR970009809A KR970009809A (en) | 1997-03-27 |
KR0173814B1 true KR0173814B1 (en) | 1999-02-01 |
Family
ID=19424662
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019950026833A KR0173814B1 (en) | 1995-08-24 | 1995-08-24 | Health aid food comprising the extract of rosa rugosa thunb |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR0173814B1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100282168B1 (en) * | 1997-12-24 | 2001-02-15 | 전기엽 | Extracts from the basement of the flower and its manufacturing method |
KR100414393B1 (en) * | 2001-01-12 | 2004-01-07 | 강원도 고성군 | Manufacturing Method for Tea and Beverage Using Rosa rugosa Thunberg |
KR100927431B1 (en) * | 2007-10-16 | 2009-11-19 | 연세대학교 산학협력단 | Composition for preventing or treating cancer, including glycolysis stem extract |
-
1995
- 1995-08-24 KR KR1019950026833A patent/KR0173814B1/en not_active IP Right Cessation
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100282168B1 (en) * | 1997-12-24 | 2001-02-15 | 전기엽 | Extracts from the basement of the flower and its manufacturing method |
KR100414393B1 (en) * | 2001-01-12 | 2004-01-07 | 강원도 고성군 | Manufacturing Method for Tea and Beverage Using Rosa rugosa Thunberg |
KR100927431B1 (en) * | 2007-10-16 | 2009-11-19 | 연세대학교 산학협력단 | Composition for preventing or treating cancer, including glycolysis stem extract |
Also Published As
Publication number | Publication date |
---|---|
KR970009809A (en) | 1997-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Osadebe et al. | Study on anti-diabetic activities of crude methanolic extracts of Loranthus micranthus (Linn.) sourced from five different host trees | |
ZA200502893B (en) | Agryrolobium roseum plant extracts for treating diabetes. | |
JP2002526379A (en) | Compositions for enhancing insulin activity and methods thereof | |
US5980902A (en) | Compositions for treating and preventing diabetes, impaired glucose tolerance and related symptoms, and methods for preparing and using such compositions | |
KR0173814B1 (en) | Health aid food comprising the extract of rosa rugosa thunb | |
US20170087201A1 (en) | Use of overground part of hedychium coronarium koenig in reducing blood glucose; extracts and compositions of overground part of hedychium coronarium koenig and their uses | |
JP2021512997A (en) | Separated windproof polysaccharides and their uses | |
US20140127333A1 (en) | Preparation, process and a regenerative method and technique for prevention, treatment and glycemic control of diabetes mellitus | |
KR0165939B1 (en) | Pharmaceutical compositions containing the extracts of lycil fructus for blood glucose reducing agent and the process for preparing them | |
EP2353605B1 (en) | Use of overground part of hedychium coronarium koenig in reducing blood glucose; extracts and compositions of overground part of hedychium coronarium koenig and their uses | |
WO1997035598A1 (en) | Pharmaceutical compositions and methods for the manufacture thereof | |
CN101744997B (en) | Extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
Ampa et al. | Evaluation of hypoglycemic, antihyperglycemic and antidiabetics properties of Trilepisium madagascariense DC Leeuwenberg (Moraceae) | |
KR20190119020A (en) | A composition for anti-inflammation comprising hemistepta lyrata extract | |
KR100213667B1 (en) | The composition showing antidiabetes | |
JP3984288B2 (en) | Preventive and therapeutic composition derived from green pepper | |
JPH0859494A (en) | Antiobesic agent and food | |
CN1403466A (en) | Syringic general saponin extractive and its prepn and medicinal composition | |
CN101745000B (en) | Extraction method of ginseng, ophiopogon root and shiandra and preparation thereof | |
CN101744999B (en) | Extraction method for ginseng, ophiopogon root and schisandra chinensis and preparation thereof | |
KR100242283B1 (en) | Compositions for treating diabetes mellitus, and a process for their preparation | |
CN1431016A (en) | Compositions of health care food for regulating blood sugar and fat as well as its preparing method | |
KR100523326B1 (en) | A Method for Extracting Antidiabetically Active Extract from Aralia elata Seemann and the Extract | |
DURAI | Effects of Turnera ulmifolia (Linn.) leaves on blood glucose level in normal and alloxan-induced diabetic rats | |
JP3320880B2 (en) | Antihypertensive and food |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20031104 Year of fee payment: 6 |
|
LAPS | Lapse due to unpaid annual fee |